Orders from 1390 SEK Free delivery from 2895 SEK Ready for pickup dead drop: collect in 5 min Free parcel delivery from 2895 SEK

Substances · Benzodiazepines and thienodiazepines

Flubromazepam

C15H10BrFN2O CAS 2647-50-9 Analytical reference material — not for human consumption
Preferred name
Flubromazepam
IUPAC name
7-bromo-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one
Parent CAS number (reference)
2647-50-9
Molecular formula
C15H10BrFN2O
Molecular weight
333.15 g/mol
InChIKey
ZRKDDZBVSZLOFS-UHFFFAOYSA-N
PubChem
CID 12947024
Source
PubChem
Verified synonyms & catalog abbreviations
Ro 05-2904 7-Bromo-2'-fluorodesmethyldiazepam

Verified Neurochemical & Toxicological Intelligence

Flubromazepam

Ultra-Long Half-Life GABA-A PAM 1,4-Benzodiazepine
Verified PubChem & CAS Identity C15H10BrFN2O · CAS 2647-50-9 · CID 12947024
Calibrated Physical Form Precision Tablets · 1 Tablet = 1 mg
≥98% Analytical Purity Verified 333.15 g/mol
Peer-Reviewed & Agency Citations 2 · verified sources

Receptor Telemetry & Mechanism of Action

GABAₐ α₂/α₃ Anxiolysis & Myorelaxation High PAM
GABAₐ α₁ Hypnotic / Sedative Drive Very High
GABAₐ α₅ Amnestic / Cognitive Modulation High

7-Bromo-2'-fluoro-1,4-benzodiazepin-2-one acting as a classic full GABA-A PAM with an elimination half-life exceeding 100 hours in human pharmacokinetic studies.

Biotransformation & Active Metabolites

Human pharmacokinetic study (Moosmann et al.) documents a ~106-hour terminal half-life via monohydroxylated metabolites.

Temporal Pharmacokinetics

Ultra-Long Half-Life GABA-A PAM — Lower milligram potency per 1 mg tablet (common literature range 4–8 mg), but extreme ~106 h half-life means slow onset (up to 2 h) and severe multi-day accumulation hazard if repeated before clearance.

  1. Onset 45–120 min
  2. Peak Window 3–6 h
  3. Total Window 12–24 h
  4. Residual / Half-Life 36–72+ h residual (T1/2 ~106 h)

Lower milligram potency per 1 mg tablet (common literature range 4–8 mg), but extreme ~106 h half-life means slow onset (up to 2 h) and severe multi-day accumulation hazard if repeated before clearance.

Quantitative Response Spectrum (Published Literature)

Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.

Threshold
2 mg
Cognitive & Sensory

Subtle threshold receptor activity (Ultra-Long Half-Life GABA-A PAM).

Somatic & Autonomic

Minimal baseline autonomic shift.

Light
2–4 mg
Cognitive & Sensory

Mild, clear-headed expression of primary class profile.

Somatic & Autonomic

Light somatic modulation.

Common Reference
4–8 mg
Cognitive & Sensory

Full characteristic neurochemical and perceptual profile documented in literature.

Somatic & Autonomic

Moderate somatic relaxation, ataxia, or autonomic tone depending on class.

Strong
8–12 mg
Cognitive & Sensory

Pronounced intensity, cognitive/motor impairment, or deep immersion.

Somatic & Autonomic

Marked somatic load and heightened adverse-event sensitivity.

Heavy / Toxic Zone
14+ mg
Cognitive & Sensory

Amnesia, blackout, acute dysphoria, confusion, or anesthetic dissociation.

Somatic & Autonomic

High toxicity zone: severe motor loss, cardiovascular strain, or respiratory hazard.

Interaction Matrix & Critical Contraindications

Critical Hazard — Never Combine

Opioids (O-DSMT, tramadol, morphine, oxycodone, fentanyl)

Synergistic brainstem respiratory depression causing unconsciousness and fatal respiratory arrest.

Alcohol, GHB/GBL, and Barbiturates

Extreme CNS depression, complete anterograde amnesia, loss of airway reflexes, and fatal aspiration.

Elevated Hazard — Avoid

Dissociatives (Ketamine, 2-FDCK, DCK, O-PCE, MXE)

Unpredictable sedation, severe motor ataxia, blackout, and emesis aspiration hazard.

Caution / Receptor Attenuation

CYP3A4 inhibitors (grapefruit juice, ketoconazole) & Stimulants

CYP3A4 inhibitors prolong plasma half-life; stimulants mask sedation until they wear off.

Structural Isomer & Sibling Comparison

Lower milligram potency per 1 mg tablet (common literature range 4–8 mg), but extreme ~106 h half-life means slow onset (up to 2 h) and severe multi-day accumulation hazard if repeated before clearance.

Physicochemical Stability & Storage

Physical Form: Precision-pressed 1 mg analytical tablets (1 tablet = 1 mg). · Parent molecule soluble in ethanol, propylene glycol, and DMSO; sparingly soluble in water.

Store sealed in a cool, dry, light-protected container away from humidity.

Cross-Tolerance & Dependence Profile

Complete cross-tolerance across all GABA-A benzodiazepines/thienodiazepines. Rapid physical dependence develops with continuous daily exposure; abrupt cessation after prolonged intake can trigger life-threatening rebound seizures and delirium.

Codes on this card

Short meanings for the abbreviations printed with this substance.

Open the full glossary →
DAT Dopamine transporter

DAT is the protein that collects dopamine back from the gap between nerve cells. A card that names DAT is quoting a laboratory result about that protein.

GABAₐ GABA-A positive modulator

GABA-A is the main inhibitory receptor for the messenger GABA. A positive modulator does not replace GABA. It makes GABA's own signal stronger when GABA is already there.

NMDA NMDA glutamate channel

NMDA is a glutamate receptor that works like a gated channel. Ketamine-type and PCP-type cards cite it when papers describe that channel as blocked.

ratio Selectivity ratio

A selectivity ratio divides two halfway numbers, such as SERT EC50 by DAT EC50, to show which target the assay reached first. The direction of the division has to be stated, or the number flips.

T½ Half-life

Half-life is the time it takes a measured concentration to fall by half. After one half-life, half remains. After another, a quarter of the original measurement remains.

1 mg / µg Calibrated Physical Form (1 mg Tablets, µg Liquid, Crystal)

Milligram-scale benzodiazepines are supplied as 1 mg tablets (1 tablet = 1 mg), microgram lysergamides as dissolved liquid (µg), and standard compounds as pure crystal or powder.

OUN / Oddech Synergistic CNS & Respiratory Depression

Combining two central nervous system depressants (such as benzodiazepines, alcohol, GHB, or opioids) multiplies sedation and can suppress brainstem breathing drive.

Tolerancja × Cross-Tolerance

When exposure to one compound reduces sensitivity to other compounds that act on the same receptor family (for example across all 5-HT2A lysergamides or all GABA-A modulators).

Comprehensive Analytical & Toxicological Monograph

Flubromazepam (7-bromo-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one; CAS 2647-50-9, PubChem CID 12947024) is a 1,4-benzodiazepine reference compound (C15H10BrFN2O, 333.15 g/mol) classified pharmacologically as a Ultra-Long Half-Life GABA-A PAM. 7-Bromo-2'-fluoro-1,4-benzodiazepin-2-one acting as a classic full GABA-A PAM with an elimination half-life exceeding 100 hours in human pharmacokinetic studies. Human pharmacokinetic study (Moosmann et al.) documents a ~106-hour terminal half-life via monohydroxylated metabolites. In published observational and toxicological literature, threshold response is noted at 2 mg, light range at 2–4 mg, common reference range at 4–8 mg, strong intensity at 8–12 mg, and heavy/adverse territory at 14+ mg, with an onset of 45–120 min, peak window of 3–6 h, and total duration of 12–24 h (36–72+ h residual (T1/2 ~106 h)). Lower milligram potency per 1 mg tablet (common literature range 4–8 mg), but extreme ~106 h half-life means slow onset (up to 2 h) and severe multi-day accumulation hazard if repeated before clearance. Critical contraindications include Opioids (O-DSMT, tramadol, morphine, oxycodone, fentanyl), Alcohol, GHB/GBL, and Barbiturates.

Chemical Architecture & Structural Profile

Flubromazepam (7-bromo-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one) is a reference compound belonging to the Benzodiazepines and thienodiazepines class, characterized by the molecular formula C15H10BrFN2O and a molar mass of 333.15 g/mol. The parent molecule is indexed under CAS registry number 2647-50-9 and in the NCBI PubChem database as CID 12947024 (Standard InChIKey: ZRKDDZBVSZLOFS-UHFFFAOYSA-N).

Citations

Reference Toxicology & Safety Profile

In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), Flubromazepam is indexed within the Benzodiazepines structural group. Toxicological notes (PsychonautWiki): low toxicity, potentially lethal when mixed with depressants like alcohol or opioids. Dependence liability (PsychonautWiki): extremely physically and psychologically addictive. Documented cross-tolerance class: benzodiazepines. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.

Citations

Analytical Use & Laboratory Notice

This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.

Citations